Copyright
©The Author(s) 2020.
World J Nephrol. Jun 30, 2020; 9(1): 1-8
Published online Jun 30, 2020. doi: 10.5527/wjn.v9.i1.1
Published online Jun 30, 2020. doi: 10.5527/wjn.v9.i1.1
Table 1 Causes of seizures in renal transplant
| Encephalopathy |
| Uraemic encephalopathy |
| Dialysis disequilibrium syndrome |
| Aluminium encephalopathy |
| Reversible posterior encephalopathy syndrome |
| Metabolic derangement |
| Hyponatremia |
| Hypocalcemia |
| Hypomagnesemia |
| Immunosuppression neurotoxicity |
| Tacrolimus (FK-506) |
| Cyclosporin |
| High dose corticosteroids |
| CNS infections |
| Meningitis |
| Encephalitis |
| Abscess |
| Drug toxicity |
| Quinolone antibiotics (e.g., Ciprofloxacin) |
| Beta Lactams (e.g., Penicillin, Mezlocillin, Cephalosporins) |
| Antidepressants |
| Bupropion HCL |
| Cerebrovascular disease |
| Subdural haematoma |
| Cerebral infarct |
| Intracerebral haemorrhage |
| Co-existing epilepsy |
| Primary CNS lymphoma |
| Action myoclonus – renal failure syndrome |
Table 2 A practical approach to generalised tonic clonic seizure in renal transplant patients (modified from Chabolla et al[14], 2006)
| Acute onset generalised tonic clonic seizure | |
| Monitor ABC | |
| IV Lorazepam 2 mg | |
| Post seizure | Persistent seizure or recurrent seizures without regaining consciousness follow status epilepticus protocol |
| Eliminate or correct identified provocative factors | |
| Neurologic examination, EEG, MRI brain | |
| If all negative, monitor without AED | |
| If any positive (Neurologic examination abnormal or EEG – Epileptic activity or MR structural lesion) OR spontaneous recurrence when monitoring without AED -> then Initiate AED | |
Table 3 Dose adjustment for antiepileptic drugs in patients with renal impairment
| GFR (mL/min) | 60-90 | 30-60 | 15-30 | < 15 | Haemodialysis |
| Levetiracetam | 500-1000 mg BD | 250-750 mg BD | 250-500 mg BD | 500-1000 mg OD | Plus 250-500 mg/d |
| Toparimate | 50% decrease | 50% decrease | 50% decrease | 50-100 mg after HD | |
| Zonisamide | 100-400 mg | 100-400 mg | |||
| Oxcarbazepine | 300-600 mg BD | 300-600 mg BD | 300 mg/d starting dose | NA | NA |
| Esclicarbazepine | None | 400-600 mg OD | 400-600 mg OD | ||
| Clobazam | None | None | None | NA | None |
| Pregabalin | None | 50% decrease | 25-125 mg/d | 25-75 mg /d | 25-150 mg after HD |
| Lacosamide | None | None | 300 mg/d | Plus < 50% after HD | |
| Rufinamide | None | None | None | NA | Plus 30% after HD |
| Vigabatrin | 25% decrease | 50% decrease | 75% decrease | NA | NA |
| Tiagabine | None | None | None | None | None |
| Lamotrigine | None | None | None | None | NA |
| Phenytoin | None | None | None | None | May need in high flux HD |
| Carbamazepine | None | NA | NA | 75% dose | Plus 75% after HD |
| Valproate | None | None | None | None | May need in high flux HD |
| Perampanel | None | None | NA | NA | NA |
| Brivaracetam | None | None | NA | NA | None |
- Citation: Sawhney H, Gill SS. Renal transplant recipient seizure practical management. World J Nephrol 2020; 9(1): 1-8
- URL: https://www.wjgnet.com/2220-6124/full/v9/i1/1.htm
- DOI: https://dx.doi.org/10.5527/wjn.v9.i1.1
